Health impact and cost-effectiveness of expanding routine immunization coverage in India through Intensified Mission Indradhanush.

IF 2.9 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Health policy and planning Pub Date : 2024-06-03 DOI:10.1093/heapol/czae024
Emma Clarke-Deelder, Christian Suharlim, Susmita Chatterjee, Allison Portnoy, Logan Brenzel, Arindam Ray, Jessica L Cohen, Nicolas A Menzies, Stephen C Resch
{"title":"Health impact and cost-effectiveness of expanding routine immunization coverage in India through Intensified Mission Indradhanush.","authors":"Emma Clarke-Deelder, Christian Suharlim, Susmita Chatterjee, Allison Portnoy, Logan Brenzel, Arindam Ray, Jessica L Cohen, Nicolas A Menzies, Stephen C Resch","doi":"10.1093/heapol/czae024","DOIUrl":null,"url":null,"abstract":"<p><p>Many children do not receive a full schedule of childhood vaccines, yet there is limited evidence on the cost-effectiveness of strategies for improving vaccination coverage. Evidence is even scarcer on the cost-effectiveness of strategies for reaching 'zero-dose children', who have not received any routine vaccines. We evaluated the cost-effectiveness of periodic intensification of routine immunization (PIRI), a widely applied strategy for increasing vaccination coverage. We focused on Intensified Mission Indradhanush (IMI), a large-scale PIRI intervention implemented in India in 2017-2018. In 40 sampled districts, we measured the incremental economic cost of IMI using primary data, and used controlled interrupted time-series regression to estimate the incremental vaccination doses delivered. We estimated deaths and disability-adjusted life years (DALYs) averted using the Lives Saved Tool and reported cost-effectiveness from immunization programme and societal perspectives. We found that, in sampled districts, IMI had an estimated incremental cost of 2021US$13.7 (95% uncertainty interval: 10.6 to 17.4) million from an immunization programme perspective and increased vaccine delivery by an estimated 2.2 (-0.5 to 4.8) million doses over a 12-month period, averting an estimated 1413 (-350 to 3129) deaths. The incremental cost from a programme perspective was $6.21 per dose ($2.80 to dominated), $82.99 per zero-dose child reached ($39.85 to dominated), $327.63 ($147.65 to dominated) per DALY averted, $360.72 ($162.56 to dominated) per life-year saved and $9701.35 ($4372.01 to dominated) per under-5 death averted. At a cost-effectiveness threshold of 1× per-capita GDP per DALY averted, IMI was estimated to be cost-effective with 90% probability. This evidence suggests IMI was both impactful and cost-effective for improving vaccination coverage, though there is a high degree of uncertainty in the results. As vaccination programmes expand coverage, unit costs may increase due to the higher costs of reaching currently unvaccinated children.</p>","PeriodicalId":12926,"journal":{"name":"Health policy and planning","volume":" ","pages":"583-592"},"PeriodicalIF":2.9000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145919/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health policy and planning","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/heapol/czae024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Many children do not receive a full schedule of childhood vaccines, yet there is limited evidence on the cost-effectiveness of strategies for improving vaccination coverage. Evidence is even scarcer on the cost-effectiveness of strategies for reaching 'zero-dose children', who have not received any routine vaccines. We evaluated the cost-effectiveness of periodic intensification of routine immunization (PIRI), a widely applied strategy for increasing vaccination coverage. We focused on Intensified Mission Indradhanush (IMI), a large-scale PIRI intervention implemented in India in 2017-2018. In 40 sampled districts, we measured the incremental economic cost of IMI using primary data, and used controlled interrupted time-series regression to estimate the incremental vaccination doses delivered. We estimated deaths and disability-adjusted life years (DALYs) averted using the Lives Saved Tool and reported cost-effectiveness from immunization programme and societal perspectives. We found that, in sampled districts, IMI had an estimated incremental cost of 2021US$13.7 (95% uncertainty interval: 10.6 to 17.4) million from an immunization programme perspective and increased vaccine delivery by an estimated 2.2 (-0.5 to 4.8) million doses over a 12-month period, averting an estimated 1413 (-350 to 3129) deaths. The incremental cost from a programme perspective was $6.21 per dose ($2.80 to dominated), $82.99 per zero-dose child reached ($39.85 to dominated), $327.63 ($147.65 to dominated) per DALY averted, $360.72 ($162.56 to dominated) per life-year saved and $9701.35 ($4372.01 to dominated) per under-5 death averted. At a cost-effectiveness threshold of 1× per-capita GDP per DALY averted, IMI was estimated to be cost-effective with 90% probability. This evidence suggests IMI was both impactful and cost-effective for improving vaccination coverage, though there is a high degree of uncertainty in the results. As vaccination programmes expand coverage, unit costs may increase due to the higher costs of reaching currently unvaccinated children.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
印度通过 Indradhanush 强化使命扩大常规免疫覆盖面的健康影响和成本效益。
许多儿童没有接种完整的儿童疫苗,但有关提高疫苗接种覆盖率策略的成本效益的证据却很有限。关于为未接种过任何常规疫苗的 "零剂量儿童 "提供接种策略的成本效益的证据更是少之又少。我们评估了定期加强常规免疫接种 (PIRI) 的成本效益,这是一种广泛应用于提高疫苗接种覆盖率的策略。我们重点关注了印度 2017-2018 年实施的大规模 PIRI 干预项目 Intensified Mission Indradhanush(IMI)。在 40 个抽样地区,我们使用原始数据测算了 IMI 的增量经济成本,并使用受控间断时间序列回归估算了增量疫苗接种剂量。我们使用 "挽救生命工具 "估算了避免的死亡人数和残疾调整生命年数,并从免疫规划和社会角度报告了成本效益。我们发现,在抽样地区,从免疫接种项目的角度来看,IMI 的增量成本估计为 2021 万美元(95% 不确定区间:1060 万至 1740 万美元),在 12 个月期间,疫苗接种量估计增加了 220 万剂(-50 万至 480 万剂),估计避免了 1413 例(-350 至 3129 例)死亡。从项目角度看,每剂疫苗的增量成本为 6.21 美元(2.80 美元为主),每名零剂量儿童的成本为 82.99 美元(39.85 美元为主),每避免一个残疾调整寿命年的成本为 327.63 美元(147.65 美元为主),每挽救一个生命年的成本为 360.72 美元(162.56 美元为主),每避免一个五岁以下儿童死亡的成本为 9701.35 美元(4372.01 美元为主)。在每避免 1x 人均国内生产总值 DALY 的成本效益阈值下,估计 IMI 具有 90% 的成本效益概率。这些证据表明,IMI 对提高疫苗接种覆盖率既有影响又有成本效益,尽管结果存在很大的不确定性。随着疫苗接种计划覆盖范围的扩大,单位成本可能会增加,因为为目前未接种疫苗的儿童接种疫苗的成本较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Health policy and planning
Health policy and planning 医学-卫生保健
CiteScore
6.00
自引率
3.10%
发文量
98
审稿时长
6 months
期刊介绍: Health Policy and Planning publishes health policy and systems research focusing on low- and middle-income countries. Our journal provides an international forum for publishing original and high-quality research that addresses questions pertinent to policy-makers, public health researchers and practitioners. Health Policy and Planning is published 10 times a year.
期刊最新文献
Conceptualising maternal mental health in rural Ghana: A realist qualitative analysis. Learning Analysis of Health System Resilience. Managing medicines in decentralisation: discrepancies between national policies and local practices in primary healthcare settings in Indonesia. What is the relationship between hospital management practices and quality of care? A systematic review of the global evidence. Development partner influence on domestic health financing contributions in Senegal: a mixed methods case study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1